Related Experiment Video
Updated: Aug 4, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Tofacitinib experience in patients with enteropathic arthritis
Pınar Akyüz Dağlı1, Abdulsamet Erden2, Serdar Can Güven1
1Ankara City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey.
Immunotherapy
|April 3, 2023
Summary
Tofacitinib, a Janus kinase inhibitor, shows promise in treating enteropathic arthritis (EA) and inflammatory bowel disease (IBD). Three patients achieved clinical remission, suggesting its potential for spondyloarthritis and IBD management.
Area of Science:
- Immunology
- Gastroenterology
- Rheumatology
Background:
- The JAK-STAT pathway plays a role in inflammatory bowel disease (IBD) and spondyloarthropathy pathogenesis.
- Enteropathic arthritis (EA) is a form of spondyloarthropathy linked to IBD.
Purpose of the Study:
- To assess the efficacy of tofacitinib, a Janus kinase inhibitor, for treating enteropathic arthritis (EA).
Main Methods:
- A case series including seven patients (four from follow-up, three from literature).
- Data collected: demographics, comorbidities, IBD/EA symptoms, treatments, and clinical/laboratory outcomes.
Main Results:
- Three out of seven patients achieved clinical and laboratory remission of both IBD and EA.
- Positive treatment response observed in patients with combined IBD and EA.
Conclusions:
- Tofacitinib demonstrated efficacy in managing enteropathic arthritis (EA) and inflammatory bowel disease (IBD).
- This Janus kinase inhibitor may be a suitable treatment option for patients with spondyloarthritis spectrum diseases and IBD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
188
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
188
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
212
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
212
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
166
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
166
01:29Inflammatory Bowel Disease IV: Pharmacological Management
165
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
165
01:20The JAK-STAT Signaling Pathway
9.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
190
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
190